Literature DB >> 22797735

PEPFAR support for the scaling up of collaborative TB/HIV activities.

Andrea A Howard1, Michel Gasana, Haileyesus Getahun, Anthony Harries, Stephen D Lawn, Bess Miller, Lisa Nelson, Joseph Sitienei, William L Coggin.   

Abstract

The US President's Emergency Plan for AIDS Relief (PEPFAR) has supported a comprehensive package of care in which interventions to address HIV-related tuberculosis (TB) have received increased funding and support in recent years. PEPFAR's TB/HIV programming is based on the World Health Organization's 12-point policy for collaborative TB/HIV activities, which are integrated into PEPFAR annual guidance. PEPFAR implementing partners have provided crucial support to TB/HIV collaboration, and as a result, PEPFAR-supported countries in sub-Saharan Africa have made significant gains in HIV testing and counseling of TB patients and linkages to HIV care and treatment, intensified TB case finding, and TB infection control. PEPFAR's support of TB/HIV integration has also included significant investment in health systems, including improved laboratory services and educating and enlarging the workforce. The scale-up of antiretroviral therapy along with support of programs to increase HIV counseling and testing and improve linkage and retention in HIV care may have considerable impact on TB morbidity and mortality, if used synergistically with isoniazid preventive therapy, intensified case finding, and infection control. Issues to be addressed by future programming include accelerating implementation of isoniazid preventive therapy, increasing access and ensuring appropriate use of new TB diagnostics, supporting early initiation of antiretroviral therapy for HIV-infected TB patients, and strengthening systems to monitor and evaluate program implementation.

Entities:  

Mesh:

Year:  2012        PMID: 22797735      PMCID: PMC4279076          DOI: 10.1097/QAI.0b013e31825cfe8e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  47 in total

1.  Preventive therapy against tuberculosis in people living with HIV.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1999-11-19

2.  Counting children: comparing reporting for paediatric HIV and tuberculosis.

Authors:  Philipp du Cros; Bern-Thomas Nyang'wa; Marianne Gale; Sarah Venis; Nathan Ford
Journal:  Bull World Health Organ       Date:  2011-12-01       Impact factor: 9.408

3.  High early death rate in tuberculosis patients in Malawi.

Authors:  A D Harries; N J Hargreaves; F Gausi; J H Kwanjana; F M Salaniponi
Journal:  Int J Tuberc Lung Dis       Date:  2001-11       Impact factor: 2.373

4.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

5.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire.

Authors:  A N Ackah; D Coulibaly; H Digbeu; K Diallo; K M Vetter; I M Coulibaly; A E Greenberg; K M De Cock
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

6.  Tuberculosis epidemics driven by HIV: is prevention better than cure?

Authors:  Christine S M Currie; Brian G Williams; Russell C H Cheng; Christopher Dye
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

7.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.

Authors:  Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

8.  Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.

Authors:  J H Perriëns; M E St Louis; Y B Mukadi; C Brown; J Prignot; F Pouthier; F Portaels; J C Willame; J K Mandala; M Kaboto
Journal:  N Engl J Med       Date:  1995-03-23       Impact factor: 91.245

Review 9.  Isoniazid preventive therapy and risk for resistant tuberculosis.

Authors:  Maria Elvira Balcells; Sara L Thomas; Peter Godfrey-Faussett; Alison D Grant
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

Review 10.  Tuberculosis among health-care workers in low- and middle-income countries: a systematic review.

Authors:  Rajnish Joshi; Arthur L Reingold; Dick Menzies; Madhukar Pai
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

View more
  10 in total

Review 1.  HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?

Authors:  Emily P Hyle; Kogieleum Naidoo; Amanda E Su; Wafaa M El-Sadr; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

2.  Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.

Authors:  Johan van Griensven; Tesfa Simegn; Mengistu Endris; Ermias Diro
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

Review 3.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

Review 4.  When to start antiretroviral therapy during tuberculosis treatment?

Authors:  Kogieleum Naidoo; Cheryl Baxter; Salim S Abdool Karim
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

Review 5.  Recent developments in the diagnosis and management of tuberculosis.

Authors:  Giorgia Sulis; Rosella Centis; Giovanni Sotgiu; Lia D'Ambrosio; Emanuele Pontali; Antonio Spanevello; Alberto Matteelli; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  NPJ Prim Care Respir Med       Date:  2016-11-03       Impact factor: 2.871

6.  Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004-2012.

Authors:  Donald J Hamel; Jean-Louis Sankalé; Jay Osi Samuels; Abdoulaye D Sarr; Beth Chaplin; Eke Ofuche; Seema T Meloni; Prosper Okonkwo; Phyllis J Kanki
Journal:  Afr J Lab Med       Date:  2015-05-14

7.  The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.

Authors:  Hannock Tweya; Caryl Feldacker; James Mpunga; Henry Kanyerere; Tom Heller; Prakash Ganesh; Dave Nkosi; Mike Kalulu; George Sinkala; Thomas Satumba; Sam Phiri
Journal:  J Int AIDS Soc       Date:  2019-04       Impact factor: 5.396

8.  Evaluation of a TB infection control implementation initiative in out-patient HIV clinics in Zambia and Botswana.

Authors:  C Emerson; V Lipke; N Kapata; N Mwananyambe; A Mwinga; M Garekwe; S Lanje; Y Moshe; S L Pals; A K Nakashima; B Miller
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

9.  Family, Community, and Health System Considerations for Reducing the Burden of Pediatric Sickle Cell Disease in Uganda Through Newborn Screening.

Authors:  Nancy S Green; Sanyukta Mathur; Sarah Kiguli; Julie Makani; Victoria Fashakin; Philip LaRussa; Magdalena Lyimo; Elaine J Abrams; Lukia Mulumba; Ezekiel Mupere
Journal:  Glob Pediatr Health       Date:  2016-04-07

10.  Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012.

Authors:  Ishani Pathmanathan; E Kainne Dokubo; Ray W Shiraishi; Simon G Agolory; Andrew F Auld; Dennis Onotu; Solomon Odafe; Ibrahim Dalhatu; Oseni Abiri; Henry C Debem; Adebobola Bashorun; Tedd Ellerbrock
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.